Findings from the phase III BEACON metastatic colorectal cancer (mCRC) study were recently published in Nature Medicine. 10% of tumours in patients with mCRC are comprised of BRAF mutations; the BEACON study "demonstrated that the BRAD inhibitor encorafenib plus the anti-EGFR monoclonal antibody cetuximab, with our without the MEK inhibitor binimetinib, improved overall survival (OS), objective response rate and progression-free survival (PFS) compared with cetuximab plus chemotherapy in patients with BRAF-mutated mCRC who has been previously treated."
To learn more about the BEACON study, click here.
Source mentioned:
Kopetz S, Murphy DA, Pu J, et al. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine; Published online 23 September 2024. DOI: https://doi.org/10.1038/s41591-024-03235-9
No comments:
Post a Comment